CYBN

Cybin Inc. (CYBN) | Rumor.io

Cybin

CYBN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,617

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.26

Market capitalization629.2M

Earnings per share-3.77

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-113.1M

Social

What share of all stock conversation is about CYBN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Jun 5

Cybin Inc. (CYBN) hit a new 52-week low and an all-time low, indicating a lack of investor confidence.
The company's recent performance has led to a loss of faith among Wall Street, with some calling for the company to be sold.
The current state of the company has led to significant losses for shareholders, with some expressing frustration and calling for the company to be sold.

Generated by AI

Sentiment

Of the messages about CYBN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	83.38% +4.69
Bearish	—	—	0% 0	16.62% -4.69

Bullish· Oct 28

$CYBN has raised $175M via direct offering to pay off debt and fuel late-stage clinical trials, solidifying its balance sheet and pipeline momentum.
The company has added strong investors like OrbiMed and Venrock, which should facilitate exits and lead to an acquisition announcement soon.
With $118M+ cash on hand and $175M in recent financing, $CYBN has a strong runway for its psychedelic biotech initiatives, including a Phase 3 program for CYB003.

Bearish· Sep 2

The CEO of Cybin Inc. (CYBN) has stepped down, which may be a sign of the company's struggles.
The departure of the CEO, particularly weeks before a critical Phase 2 readout, raises concerns about the company's leadership and potential for bad news.
Institutional investors, such as RA Capital, have dumped their positions in CYBN, indicating a loss of confidence in the company.

Generated by AI

Topics

Of the messages about CYBN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	50.07%
Technical Analysis	0%	0%	0%	30.8%
Analysts	0%	0%	0%	10.25%
Controversies	0%	0%	0%	0.46%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	8.42%

Analysts· Apr 28

Analysts report that Cybin Inc. (CYBN) may uplist to NASDAQ in Q2 or Q4, with a potential price target of $10.00 USD.
The uplisting is seen as a positive development, with some considering the company undervalued at current prices.
Analysts believe the potential NASDAQ listing could have a significant impact on the company's valuation and overall market perception.

Announcements· Oct 28

Cybin Inc. ($CYBN) announced a $175 million registered direct offering of 22.3 million common shares and pre-funded warrants at $6.51 each.
The funding will be used to support clinical stage programs, including the repayment of a high-trail convertible note in full.
The offering includes participation from prominent biotech investors, including Venrock, OrbiMed, and Point72.

Generated by AI

Community

Of the messages about CYBN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.11%	5%	29.82%	64.04%
Newcomers	91.89%	95%	70.18%	35.96%

Regulars· May 29

The irrational valuation of Cybin Inc. is a notable concern among regular participants.
There are issues with buying Cybin on certain platforms, such as Schwab, requiring a manual order.
Despite the challenges, the company's low price is seen as a buying opportunity by some regulars.

Newcomers· Oct 28

$CYBN's recent $175M PIPE was led by notable investors, including Venrock Partners and OrbiMed, with shares sold at $6.51 each.
The company's deuterated psilocin (CYB003) is expected to be a game-changer, but phase 3 data are still a year away, with GAD data expected in Q4-Q1'2025.
$CYBN's recent financing and strong cash position ($118M+) are seen as a positive, with the stock price experiencing a big move up on news of the offering.

Generated by AI

Cybin (NasdaqGM:HELP), which is rebranding as Helus Pharma, has just wrapped up a pivotal shareholder meeting approving a legal name change and confirming its full director slate for the coming year. For investors tracking Cybin, the legal rebrand to Helus Pharma comes after a sharp run in the share price over recent months. The 90 day share price return is 116.28% and the 1 year total shareholder return is 115.56%. In contrast, the 3 year total shareholder return is down 37.40% and the 5...

5d agoYahoo Finance

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead

6d agoYahoo Finance

Helus Pharma shareholders approve name change from Cybin Inc.

7d agoInvesting.com

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting hol

7d agoYahoo Finance

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv

8d agoYahoo Finance

Also Discussed

Investors talking about CYBN also mention

#	Name	Attention
1	Compass Pathways plc - ADRCMPS	0.03%+0.02
2	Definium Therapeutics, Inc.MNMD	0%+0
3	ATA Inc-ChinaATAI	0%new
4	GH Research PLCGHRS	0%0
5	AdvisorShares Psychedelics ETFPSIL	0.02%+0.01
6	GBNH - Greenbrook TMS Inc.	——
7	BNOX - Bionomics Limited	——
8	SEEL - Seelos Therapeutics, Inc.	——
9	Bright Minds Biosciences Inc.DRUG	0%new
10	NM - Navios Maritime Holdings Inc.	——

Cybin Inc.

Healthcare
Biotechnology

Cybin Inc. is a biotechnology company specializing in advancing psychedelic therapeutics. It focuses on developing drug candidates based on psilocybin and other psychoactive compounds for mental health applications. Cybin aims to innovate new formulations and delivery methods to enhance efficacy and safety profiles. The company operates within the rapidly evolving biopharmaceutical sector, targeting neuropsychiatric disorders such as depression, anxiety, and substance use disorders. Cybin’s role in the financial markets represents the growing investor interest in the mental health and psychedelics space, reflecting broader trends in pharmaceutical innovation and alternative medicine research. Its stock is listed on multiple exchanges, including a secondary listing on the Berlin Stock Exchange, which expands its access to European investors and highlights its international presence in capital markets.

Website

Location

100 King Street West

Toronto, ON, M5X 1C9

Canada

Social

What share of all stock conversation is about CYBN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Jun 5

Cybin Inc. (CYBN) hit a new 52-week low and an all-time low, indicating a lack of investor confidence.
The company's recent performance has led to a loss of faith among Wall Street, with some calling for the company to be sold.
The current state of the company has led to significant losses for shareholders, with some expressing frustration and calling for the company to be sold.

Generated by AI

Sentiment

Of the messages about CYBN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	83.38% +4.69
Bearish	—	—	0% 0	16.62% -4.69

Bullish· Oct 28

$CYBN has raised $175M via direct offering to pay off debt and fuel late-stage clinical trials, solidifying its balance sheet and pipeline momentum.
The company has added strong investors like OrbiMed and Venrock, which should facilitate exits and lead to an acquisition announcement soon.
With $118M+ cash on hand and $175M in recent financing, $CYBN has a strong runway for its psychedelic biotech initiatives, including a Phase 3 program for CYB003.

Bearish· Sep 2

The CEO of Cybin Inc. (CYBN) has stepped down, which may be a sign of the company's struggles.
The departure of the CEO, particularly weeks before a critical Phase 2 readout, raises concerns about the company's leadership and potential for bad news.
Institutional investors, such as RA Capital, have dumped their positions in CYBN, indicating a loss of confidence in the company.

Generated by AI

Topics

Of the messages about CYBN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	50.07%
Technical Analysis	0%	0%	0%	30.8%
Analysts	0%	0%	0%	10.25%
Controversies	0%	0%	0%	0.46%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	8.42%

Analysts· Apr 28

Analysts report that Cybin Inc. (CYBN) may uplist to NASDAQ in Q2 or Q4, with a potential price target of $10.00 USD.
The uplisting is seen as a positive development, with some considering the company undervalued at current prices.
Analysts believe the potential NASDAQ listing could have a significant impact on the company's valuation and overall market perception.

Announcements· Oct 28

Cybin Inc. ($CYBN) announced a $175 million registered direct offering of 22.3 million common shares and pre-funded warrants at $6.51 each.
The funding will be used to support clinical stage programs, including the repayment of a high-trail convertible note in full.
The offering includes participation from prominent biotech investors, including Venrock, OrbiMed, and Point72.

Generated by AI

Community

Of the messages about CYBN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.11%	5%	29.82%	64.04%
Newcomers	91.89%	95%	70.18%	35.96%

Regulars· May 29

The irrational valuation of Cybin Inc. is a notable concern among regular participants.
There are issues with buying Cybin on certain platforms, such as Schwab, requiring a manual order.
Despite the challenges, the company's low price is seen as a buying opportunity by some regulars.

Newcomers· Oct 28

$CYBN's recent $175M PIPE was led by notable investors, including Venrock Partners and OrbiMed, with shares sold at $6.51 each.
The company's deuterated psilocin (CYB003) is expected to be a game-changer, but phase 3 data are still a year away, with GAD data expected in Q4-Q1'2025.
$CYBN's recent financing and strong cash position ($118M+) are seen as a positive, with the stock price experiencing a big move up on news of the offering.

Generated by AI

Cybin

Social

Jun 5

Bullish· Oct 28

Bearish· Sep 2

Analysts· Apr 28

Announcements· Oct 28

Regulars· May 29

Newcomers· Oct 28

Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data

Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma shareholders approve name change from Cybin Inc.

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Also Discussed

Cybin Inc.

Company Information

Location

Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data

Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma shareholders approve name change from Cybin Inc.

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Also Discussed

Social

Jun 5

Bullish· Oct 28

Bearish· Sep 2

Analysts· Apr 28

Announcements· Oct 28

Regulars· May 29

Newcomers· Oct 28